Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...

Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.

Heron Therapeutics (HRTX) stock gains as company receives FDA nod for a new mechanism to prepare its Zynrelef postoperative ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

In the assessment of 12-month price targets, analysts unveil insights for Pacira BioSciences, presenting an average target of ...

Regional anesthesia reduced acute and chronic postoperative pain and decreased the incidence of prolonged opioid use after ...

US FDA approves Heron Therapeutics’ prior approval supplement application for Zynrelef vial access needle: San Diego Thursday, September 26, 2024, 17:00 Hrs [IST] Heron Therapeu ...

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced ...

On top of personalized education, one of the key differences we saw from VR’s medical application is how well it can prepare ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...